New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For GOOG;EMC;VMW;INTC;GILD;FRX From The Last 14 Days
Check below for free stories on GOOG;EMC;VMW;INTC;GILD;FRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>
April 22, 2014
15:32 EDTEMCNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Procter & Gamble (PG), consensus $1.02; Boeing (BA), consensus $1.56; Biogen Idec (BIIB), consensus $2.56; Dow Chemical (DOW), consensus 71c; EMC Corporation (EMC), consensus 35c; Thermo Fisher (TMO), consensus $1.40; Praxair (PX), consensus $1.51; General Dynamics (GD), consensus $1.64; Johnson Controls (JCI), consensus 65c; Norfolk Southern (NSC), consensus $1.15; Reynolds American (RAI), consensus 74c; Delta Air Lines (DAL), consensus 29c; Northrop Grumman (NOC), consensus $2.15; Air Products & Chemicals (APD), consensus $1.35; TD Ameritrade (AMTD), consensus 34c; Ingersoll-Rand (IR), consensus 26c; Dr Pepper Snapple (DPS), consensus 59c; Polaris Industries (PII), consensus $1.16; Ryder System (R), consensus 87c.
15:32 EDTVMW, GILDNotable companies reporting after market close
Subscribe for More Information
15:10 EDTEMCEarnings Preview: EMC shares up 6% since Q4 report
Subscribe for More Information
13:18 EDTGOOGOpera says Android overtook iOS in mobile ad traffic
Subscribe for More Information
13:07 EDTGOOGYouTube's head of product leaving company, Re/code reports
Subscribe for More Information
07:36 EDTGILDGilead weakness has created attractive entry point, says Stifel
Subscribe for More Information
06:37 EDTGOOGCompanies with cloud businesses worried about Aereo case, Re/code says
Subscribe for More Information
April 21, 2014
16:32 EDTGILDU.S. FDA accepts Gilead's NDA's for Cobicistat and Elvitegravir
Gilead Sciences announced that the U.S. FDA has accepted the company’s refiling of two New Drug Applications for cobicistat, a pharmacoenhancing or “boosting” agent that increases blood levels of the protease inhibitors atazanavir and darunavir to enable once-daily dosing of these medicines in HIV therapy, and elvitegravir, an integrase inhibitor for the treatment of HIV-1 infection in treatment-experienced adults. The FDA has set target review dates under the Prescription Drug User Fee Act of October 3 for cobicistat and October 4 for elvitegravir. Gilead submitted NDAs for cobicistat and elvitegravir in June 2012. In April 2013, the company received Complete Response Letters from the FDA. In its communications, the agency stated that it could not approve the cobicistat and elvitegravir applications in their current forms, citing deficiencies in documentation and validation of certain quality testing procedures and methods that were observed during inspections. Gilead has worked with the FDA to address the questions raised in the Complete Response Letters. Cobicistat and elvitegravir are components of Gilead’s Stribild, a once-daily single tablet regimen for the treatment of HIV-1 infection. Stribild was approved in the United States in August 2012. Cobicistat is approved under the tradename Tybost and elvitegravir is approved under the tradename Vitekta in Europe, Canada and Australia.
16:01 EDTGILDOptions Update; April 21, 2014
iPath S&P 500 VIX Short-Term Futures down 78c to 40.03. Option volume leaders: AAPL C GILD NFLX TSLA TWTR FB WLT according to Track Data.
14:24 EDTGILDCVS wants price competition to Gilead's hepatitis C drug, Bloomberg says
CVS said it may try to slow uptake of Gilead's new hepatitis C drug, which costs $1,000 per pill. Bloomberg cites an interview with CVS's CMO Troy Brennan.
13:41 EDTEMCEMC April weekly volatility elevated into Q1 and outlook
EMC April weekly call option implied volatility is at 38, May is at 22, June is at 21; compared to its 26-week average of 22 according to Track Data, suggesting large near term price movement into the expected release of Q1 results on April 23.
13:36 EDTGOOGGoogle wants to add encryption tools to Gmail, VentureBeat says
Subscribe for More Information
10:49 EDTGOOGOptions with decreasing implied volatility: SRPT NSR INFY CMG GOOG
Subscribe for More Information
10:20 EDTGILDGilead volatility increases into Q1 and outlook
Gilead April weekly call option implied volatility is at 65, May is at 40, June is at 34, August is at 33; compared to its 26-week average of 34 according to Track Data, suggesting large near term price movement into the expected release of Q1 result son April 22.
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
08:03 EDTVMWVMware volatility elevated into Q1 and revenue growth outlook
Subscribe for More Information
07:43 EDTINTCSMART Technologies announces share structure changes after board resignations
Subscribe for More Information
07:21 EDTGILDFDA Pediatric Advisory Committee to hold a meeting
The Committee discusses pediatric-focused safety reviews including MDT's Activa Dystonia Therapy, (BAX's Advate and Tisseel, NVS' Famvir, Tibotec's (JNJ subsidiary) Intelence, UCB Pharma's Keppra, MRK's Maxalt, BAYRY's Natazia, Digestive Care's Pertzye, JNJ's Prezista, BMY's Reyataz, SNY's Sklice, PFE's Torisel, Aptalis' Ultresa, and GILD's Viread in a meeting being held in Bethesda, Maryland on April 21 at 8 am. Webcast Link
06:48 EDTGOOGMicrosoft faces internal & external conflicts in three segments, DigiTimes says
Subscribe for More Information
06:45 EDTGOOGApple and Google compete to offer exclusive game apps, WSJ reports
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use